Covered recipient · General Payments record
GEORGE S REYNA
Allopathic & Osteopathic Physicians Ophthalmology
General Payments · PY2019–2025
$2,518.13
- Reported across 60 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $706.23 | 17 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | $259.08 | 3 |
| Bausch & Lomb Americas Inc. | $159.98 | 3 |
| ABBVIE INC. | $94.62 | 4 |
| Amgen Inc. | $84.60 | 4 |
| BIOTISSUE HOLDINGS INC. | $54.04 | 1 |
| Alcon Vision LLC | $53.91 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $16.65 | 01/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203836323 | CMS |
| ABBVIE INC. | $30.01 | 03/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203836329 | CMS |
| ABBVIE INC. | $29.16 | 03/27/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203836335 | CMS |
| ABBVIE INC. | $18.80 | 09/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203836341 | CMS |
| Alcon Vision LLC | $29.27 | 05/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1207438752 | CMS |
| Alcon Vision LLC | $24.64 | 11/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1207438878 | CMS |
| Amgen Inc. | $21.40 | 02/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228644491 | CMS |
| Amgen Inc. | $19.09 | 03/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228644489 | CMS |
| Amgen Inc. | $20.63 | 04/24/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228644493 | CMS |
| Amgen Inc. | $23.48 | 07/21/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228644495 | CMS |
| Bausch & Lomb Americas Inc. | $17.98 | 03/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1254785403 | CMS |
| Bausch & Lomb Americas Inc. | $17.02 | 05/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1254785399 | CMS |
| Bausch & Lomb Americas Inc. | $124.98 | 11/13/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1254785401 | CMS |
| BIOTISSUE HOLDINGS INC. | $54.04 | 07/10/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1240156117 | CMS |
| Tarsus Pharmaceuticals, Inc. | $109.50 | 02/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1233898569 | CMS |
| Tarsus Pharmaceuticals, Inc. | $28.22 | 07/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1233898571 | CMS |
| Tarsus Pharmaceuticals, Inc. | $121.36 | 09/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1233898573 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2023, 2024, 2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.